Home > Publications database > Targeted next-generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance. > print

001     120541
005     20240228145451.0
024 7 _ |a 10.1002/gcc.22431
|2 doi
024 7 _ |a pmid:27792260
|2 pmid
024 7 _ |a 1045-2257
|2 ISSN
024 7 _ |a 1098-2264
|2 ISSN
024 7 _ |a altmetric:13158887
|2 altmetric
037 _ _ |a DKFZ-2017-00970
041 _ _ |a eng
082 _ _ |a 570
100 1 _ |a Pfarr, Nicole
|b 0
245 _ _ |a Targeted next-generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance.
260 _ _ |a New York, NY
|c 2017
|b Wiley-Liss
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1533719288_22870
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a HER2-positive breast cancers are a heterogeneous group of tumors, which share amplification and overexpression of HER2. In routine diagnostics, the HER2 (ERBB2) status is currently assessed by immunohistochemistry (IHC) and in situ hybridization (ISH). Data on targeted next-generation sequencing (NGS) approaches that could be used to determine the HER2 status are sparse. Employing two breast cancer-related gene panels, we performed targeted NGS of 41 FFPE breast cancers for which full pathological work-up including ISH and IHC results was available. Selected cases were analyzed by qPCR. Of the 41 cases, the HER2 status of the 4 HER2-positive and 6 HER2-negative tumors was independently detected by our NGS approach achieving a concordance rate of 100%. The remaining 31 cases were equivocal HER2 cases by IHC of which 5 showed amplification of HER2 by ISH. Our NGS approach classified all non-amplified cases correctly as HER2 negative and corroborated all but one of the 5 cases with amplified HER2 as detected by ISH. For the overall cohort, concordance between the gold standard and NGS was 97.6% (sensitivity 88.9% and specificity 100%). Additionally, we observed mutations in PIK3CA (44%), HER2 (8%), and CDH1 (6%) among others. Amplifications were found in CCND1 (12%), followed by MYC (10%) and EGFR (2%) and deletions in CDKN2A (10%), MAP2K4 and PIK3R1 (2% each). We here show that targeted NGS data can be used to interrogate the HER2 status with high specificity and high concordance with gold standard methods. Moreover, this approach identifies additional genetic events that may be clinically exploitable. © 2016 Wiley Periodicals, Inc.
536 _ _ |a 317 - Translational cancer research (POF3-317)
|0 G:(DE-HGF)POF3-317
|c POF3-317
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Penzel, Roland
|b 1
700 1 _ |a Endris, Volker
|b 2
700 1 _ |a Lier, Clemens
|b 3
700 1 _ |a Flechtenmacher, Christa
|b 4
700 1 _ |a Volckmar, Anna-Lena
|b 5
700 1 _ |a Kirchner, Martina
|0 P:(DE-He78)3b9d10db5dbbf9eb21d02f77d99c8ac9
|b 6
|u dkfz
700 1 _ |a Budczies, Jan
|b 7
700 1 _ |a Leichsenring, Jonas
|b 8
700 1 _ |a Herpel, Esther
|b 9
700 1 _ |a Noske, Aurelia
|b 10
700 1 _ |a Weichert, Wilko
|0 P:(DE-HGF)0
|b 11
700 1 _ |a Schneeweiss, Andreas
|0 P:(DE-He78)2dc788b30e99b99a3f9b45ca60f3939d
|b 12
700 1 _ |a Schirmacher, Peter
|0 P:(DE-HGF)0
|b 13
700 1 _ |a Sinn, Hans-Peter
|0 P:(DE-HGF)0
|b 14
700 1 _ |a Stenzinger, Albrecht
|0 P:(DE-HGF)0
|b 15
773 _ _ |a 10.1002/gcc.22431
|g Vol. 56, no. 4, p. 255 - 265
|0 PERI:(DE-600)1492641-6
|n 4
|p 255 - 265
|t Genes, chromosomes & cancer
|v 56
|y 2017
|x 1045-2257
909 C O |p VDB
|o oai:inrepo02.dkfz.de:120541
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)3b9d10db5dbbf9eb21d02f77d99c8ac9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-He78)2dc788b30e99b99a3f9b45ca60f3939d
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-HGF)0
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 14
|6 P:(DE-HGF)0
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 15
|6 P:(DE-HGF)0
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-317
|2 G:(DE-HGF)POF3-300
|v Translational cancer research
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2017
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b GENE CHROMOSOME CANC : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 1 _ |0 I:(DE-He78)L701-20160331
|k L701
|l DKTK München
|x 0
920 1 _ |0 I:(DE-He78)G825-20160331
|k G825
|l MT NCT Mol. Pathology Core
|x 1
920 1 _ |0 I:(DE-He78)V964-20160331
|k V964
|l NCT-KliHD
|x 2
920 1 _ |0 I:(DE-He78)L101-20160331
|k L101
|l DKTK Heidelberg
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)L701-20160331
980 _ _ |a I:(DE-He78)G825-20160331
980 _ _ |a I:(DE-He78)V964-20160331
980 _ _ |a I:(DE-He78)L101-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21